Category Archives: General HIV+ population
Reviews on HIV+ people where the population is not specified
Interventions for previously untreated patients with AIDS-associated Non-Hodgkin’s Lymphoma
BACKGROUND: Human immunodeficiency virus (HIV) infection is known to be associated with an increased risk of non-Hodgkin’s lymphoma (NHL). The majority of lymphomas (>80%) occurring during immunosuppression are aggressive B-cell...
HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: A systematic review and meta-analysis
BACKGROUND: The detection of mutations associated with drug resistance in HIV type-1 might be increased by applying minority species assays capable of identifying low frequency mutations in comparison with the...
Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: A systematic review
BACKGROUND: HIV and AIDS are significant and growing public health concerns in southern Africa. The majority of countries in the region have national adult HIV prevalence estimates exceeding 10 percent....
Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole
BACKGROUND: Opportunistic infections continue to cause a significant amount of morbidity and mortality worldwide in patients infected with HIV. Trimethoprim-sulfamethoxazole (cotrimoxazole) is used in the treatment and prophylaxis of several...
Isoniazid preventive therapy and risk for resistant tuberculosis
In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread implementation. We...
Treatment of active tuberculosis in HIV-coinfected patients: A systematic review and meta-analysis.
Rationale: Patients with HIV-related tuberculosis (TB) have an increased risk of death, TB treatment failure, and relapse. There are several areas of uncertainty regarding the treatment of active TB in...
Atazanavir: A new protease inhibitor to treat HIV infection
PURPOSE: The pharmacology, pharmacokinetics, and clinical trials of and drug interactions and formulary considerations associated with atazanavir, the newest protease inhibitor (PI) to treat human immunodeficiency virus (HIV) infection, are...
Efficacy and cost-effectiveness of the first generation of HIV prevention interventions for people with severe and persistent mental illness
BACKGROUND: People with serious mental illness are at elevated risk for human immunodeficiency virus (HIV) infection. A small body of published research has evaluated the efficacy of HIV prevention interventions...
Treatment of Kaposi’s sarcoma in HIV-1 infected individuals with emphasis on resource poor settings
BACKGROUND: In many countries, Kaposi’s sarcoma (KS) is the commonest malignancy among individuals infected with the human immunodeficiency virus-1 (HIV) and is a cause of substantial morbidity and mortality. OBJECTIVES:...
Lessons learned from use of highly active antiretroviral therapy in Africa
BACKGROUND: Because antiretrovirals are becoming increasingly available in developing countries, we reviewed the findings of studies that have documented highly active antiretroviral therapy (HAART) use in Africa to identify lessons...
